Table 3.
Treatments and outcomes
| No. | Sex/age | ECOG PS | Pathology | Major sites | Multiple/CSF | Surgery | Tx.Cohort 1 or 2 | Response | status | OS(months) |
|---|---|---|---|---|---|---|---|---|---|---|
| 01 | F/59 | 1 | PTCL | Rt. frontal | No/no | Resection | 2 | CR | AIR | 22.9+ |
| 02 | F/37 | 1 | PTCL | Rt. Frontoparietal | No/no | Biopsy | 1 | CR | AIR | 118.7+ |
| 03 | F/34 | 2 | PTCL | Rt. Frontoparietal, occipital | YES/no | Resection | 2 | PD | DOD | 23.3 |
| 04 | F/33 | 2 | PTCL | Rt. parietal, occipital, temporal | Yes/no | Biopsy | 1 | CR | AlR | 121.2+ |
| 05 | M/31 | 1 | PTCL | Rt. occipital | No/no | Biopsy | 1 | CR | AlR | 121.6+ |
| 06 | M/22 | 4 | PTCL | Medulla,Spinal cord,Lt.parietal lobe | Yes/no | Biopsy | 2 | SD | AWD | 2.5+ |
| 07 | F/18 | 1 | PTCL | Basal ganglia, Hippocampus | Yes/no | Biopsy | 2 | CR | AIR | 15.3+ |
| 08 | F/26 | 2 | T-lineage | Medulla, Both. frontal Lt. temporal | Yes/no | Biopsy | 2 | PD | DOD | 7.7 |
| 09 | F/46 | 1 | T-lineage | Frontoparietal | No/no | Resection | 1 | CR | AIR | 123.8+ |
| 10 | M/57 | 1 | MZBCL | Thalamus | No/no | Biopsy | 2 | CR | AlR | 39.4+ |
| 11 | M/26 | 2 | B-lineage | Rt. Frontoparietal | No/yes | Biopsy | 1 | CR | AIR | 103.5+ |
| 12 | M/50 | 2 | LPL | T4 Spinal cord | No/no | Resection | Corpectomy | CR | AIR | 51.0+ |
| 13 | M/38 | 1 | LPL | Corpus callosum, Lt. frontal | Yes/no | Biopsy | 2 | SD | AWD | 2.6+ |
| 14 | F/43 | 3 | BL | Medulla, LEMS | No/yes | Biopsy | 2 | PD | DOD | 7.6 |
| 15 | F/20 | 1 | B-lineage | Lt. parietal | No/no | Biopsy | 2 | PD | F/L | 78.4 |
PTCL peripheral T-cell lymphoma, MZBCL marginal zone B-cell lymphoma, LPL lymphoplasmacytic lymphoma, BL Burkitt’s lymphoma, LEMS leptomeningeal seeding, CR complete response, PR partial response, SD stable disease, PD progressive disease, AIR alive in remission, AWD alive with disease, DOD dead of disease, F/L follow-up loss, Tx treatment, ECOG PS Eastern Cooperative Oncology Group performance score